Patritumab deruxtecan

Patritumab deruxtecan用途

Patritumab deruxtecan(HER3 DXd)是一种抗体-药物偶联物(ADC),由全人抗HER3 IgG1单克隆抗体Patrituma(HY-P99275)组成,通过基于四肽的可裂解接头连接到拓扑异构酶I抑制剂有效载荷上。Patritumab deruxtecan显示出抗癌活性[1]。

Patritumab deruxtecan名称

[ CAS 号 ]:
2227102-46-5

[ 英文名 ]:
Patritumab deruxtecan

Patritumab deruxtecan生物活性

[ 描述 ]:

[ 相关类别 ]:

研究领域 >> 癌症

[体外研究]

帕特里图马对表达赫3突变的乳腺癌细胞表现出活性,无论她2是否过表达[1]。 Patritumab deruxtecan(0-100 nM)以浓度依赖性方式结合所有赫3突变体和 HER3WT MDA-MB-231型细胞的表面,但不结合 HER3^{电动汽车细胞[1].}

[参考文献]

[1]. Koyama K, et al. Patritumab deruxtecan (HER3-DXd), a novel HER3 directed antibody drug conjugate, exhibits in vitro activity against breast cancer cells expressing HER3 mutations with and without HER2 overexpression. PLoS One. 2022 May 3;17(5):e0267027.

Patritumab deruxtecan物理化学性质

暂时没有任何物化性质资料

Patritumab deruxtecan

Patritumab deruxtecan用途

Patritumab deruxtecan名称

Patritumab deruxtecan生物活性

Patritumab deruxtecan物理化学性质

推荐生产厂家/供应商：

相关化合物